POCT INR
[POCT INR]
EPTIS factsheet 142678 | Last revision 2024-05-21 | URL: https://www.eptis.bam.de/pts142678 https://www.eptis.bam.de/pts142678
| PT provider | |||||||
| PT provider | Weqas Weqas | ||||||
| Based in | United Kingdom | ||||||
| Language(s) | |||||||
| Remarks | Patients receiving warfarin, a Vitamin K antagonist (VKA) as anticoagulant therapy will have their International normalized ratio (INR) measured regularly to ensure that their medication is effective, and the dose adjusted accordingly to maintain the INR within the appropriate range. Warfarin, the most commonly used VKA, is a coumarin derivative that acts by inhibiting vitamin K dependent clotting factors (II, VII, IX, X) in addition to the anticoagulant proteins C and S. The INR calculation is based on a standardised ratio of the patient’s Prothrombin time, (PT) versus a normal control sample. Therefore, the INR of a healthy individual not on anticoagulation therapy would be 1.0. PT measures the time taken (in seconds) for the blood to clot following addition of thromboplastin, an activating enzyme. Warfarin is licensed for prophylaxis of embolization in rheumatic heart disease and atrial fibrillation, prophylaxis after insertion of prosthetic heart valve, prophylaxis and treatment of venous thrombosis (DVT), pulmonary embolism (PE), and in transient ischaemic attacks. The programme includes a panel of samples spanning the pathological range, however the majority of samples distributed in the year are specifically selected to challenge the therapeutic targets of 2.5 and 3.5. One liquid stable sample is distributed every 2 months, a minimum of six samples per year, some of which are distributed on a number of occasions. This allows for the assessment of the organisation’s and method’s performance, including linearity, bias, within and between batch imprecision. Key Features: - Stable samples supplied ready to use, no pre-analytical preparation is required. - Panel of samples distributed over the year that spans the therapeutic target ranges. - Scoring based on Milan Model 3 performance specification. For more information: https://www.weqas.com/services/poct-eqa/poct-inr/ or contact@weqas.com | ||||||
| Keywords | |||||||
| Product groups |
Health care / medical devices
|
||||||
| Testing fields |
Medical analysis
|
||||||
| Technical details | |||||||
|
|||||||
| Aims of the PT scheme | |||||||
| Target group of participants | Laboratory Diagnostic Services and Point of Care Testing Services. The INR EQA control material is suitable for use with the majority of POCT devices including the Abbott-i-STAT, the Roche CoaguChek range of devices, and the Siemens Xprecia Stride. | ||||||
| Linked to specific legislation / standards | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Additional, subsidiary aims | validation of testing methods | ||||||
| Number of participants | |||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/ IEC 17043 |
||||||
| Operation is commissioned / requested by | |||||||
| Fees and frequency | |||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | ||||||
| Regularly operated | Yes (Frequency: Bimonthly. Samples: 1 x 0.3mL) | ||||||
| Year of first operation | 2009 | ||||||
| Contact details of the PT provider | |||||||
| Provider | Contact person | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.